NanoViricides to Present at the Biotech Showcase in San Fransisco on Tuesday, January 14, 2025
NanoViricides (NYSE American:NNVC) announced its upcoming presentation at Biotech Showcase™ 2025 in San Francisco on Tuesday, January 14, 2025, at 2:30pm PT. The presentation will be held at the Hilton San Francisco - Union Square.
The company will showcase its Phase II-ready drug NV-387, which has demonstrated broad-spectrum antiviral activity. NV-387 has shown superior effectiveness compared to existing treatments like Tamiflu®, Rapivab®, and Xofluza® in treating Influenza A. The drug has also demonstrated promising results against MPox, Smallpox, RSV, and SARS-CoV-2 infections in animal models.
NV-387's unique mechanism mimics a host-side feature used by 90-95% of human pathogenic viruses, making it difficult for viruses to develop resistance. The overall market size for NV-387 indications is estimated to exceed $10 billion. The company has also developed a platform enabling non-oral drugs to be delivered as active oral drugs.
NanoViricides (NYSE American:NNVC) ha annunciato la sua prossima presentazione al Biotech Showcase™ 2025 a San Francisco, martedì 14 gennaio 2025, alle 14:30 PT. La presentazione si terrà presso l'Hilton San Francisco - Union Square.
L'azienda presenterà il suo farmaco NV-387 pronto per la Fase II, che ha dimostrato un'attività antivirale ad ampio spettro. NV-387 ha mostrato un'efficacia superiore rispetto ai trattamenti esistenti come Tamiflu®, Rapivab® e Xofluza® nel trattamento dell'Influenza A. Il farmaco ha anche mostrato risultati promettenti contro le infezioni da MPox, vaiolo, RSV e SARS-CoV-2 in modelli animali.
Il meccanismo unico di NV-387 imita una caratteristica della parte ospite utilizzata dal 90-95% dei virus patogeni umani, rendendo difficile per i virus sviluppare resistenza. La dimensione complessiva del mercato per le indicazioni di NV-387 è stimata a superare $10 miliardi. L'azienda ha anche sviluppato una piattaforma che consente la somministrazione di farmaci non orali come farmaci orali attivi.
NanoViricides (NYSE American:NNVC) anunció su próxima presentación en el Biotech Showcase™ 2025 en San Francisco el martes 14 de enero de 2025 a las 2:30 p.m. PT. La presentación se llevará a cabo en el Hilton San Francisco - Union Square.
La empresa mostrará su fármaco NV-387 listo para Fase II, que ha demostrado una actividad antiviral de amplio espectro. NV-387 ha evidenciado una eficacia superior en comparación con tratamientos existentes como Tamiflu®, Rapivab® y Xofluza® para el tratamiento de la Influenza A. El fármaco también ha mostrado resultados prometedores contra infecciones de MPox, viruela, VSR y SARS-CoV-2 en modelos animales.
El mecanismo único de NV-387 imita una característica del lado del huésped utilizada por el 90-95% de los virus patógenos humanos, lo que dificulta que los virus desarrollen resistencia. Se estima que el tamaño total del mercado para las indicaciones de NV-387 superará los $10 mil millones. La empresa también ha desarrollado una plataforma que permite que los medicamentos no orales se administren como medicamentos orales activos.
NanoViricides (NYSE American:NNVC)는 2025년 1월 14일 화요일 오후 2:30 PT에 샌프란시스코에서 열리는 Biotech Showcase™ 2025에 대한 발표를 곧 진행할 것이라고 발표했습니다. 발표는 힐튼 샌프란시스코 - 유니온 스퀘어에서 열립니다.
회사는 광범위한 항바이러스 활성을 입증한 2상 준비 완료 약물 NV-387를 선보일 예정입니다. NV-387는 인플루엔자 A 치료에 있어 Tamiflu®, Rapivab®, Xofluza®과 같은 기존 치료법에 비해 뛰어난 효능을 보여주었습니다. 이 약물은 또한 동물 모델에서 MPox, 천연두, RSV 및 SARS-CoV-2 감염에 대한 유망한 결과를 입증했습니다.
NV-387의 독특한 메커니즘은 90-95%의 인간 병원체 바이러스가 사용하는 숙주 측의 특징을 모방하여, 바이러스가 저항성을 발전시키기 어렵게 만듭니다. NV-387 적응증에 대한 전체 시장 규모는 $10억을 초과할 것으로 추정됩니다. 또한, 회사는 비경구 약물이 활성 경구 약물로 전달될 수 있도록 하는 플랫폼을 개발했습니다.
NanoViricides (NYSE American:NNVC) a annoncé sa prochaine présentation au Biotech Showcase™ 2025 à San Francisco le mardi 14 janvier 2025 à 14h30 PT. La présentation se tiendra au Hilton San Francisco - Union Square.
L'entreprise mettra en avant son médicament NV-387 prêt pour la phase II, qui a démontré une activité antivirale à large spectre. NV-387 a montré une efficacité supérieure par rapport aux traitements existants tels que Tamiflu®, Rapivab® et Xofluza® dans le traitement de l'influenza A. Le médicament a également montré des résultats prometteurs contre les infections par MPox, la variole, le VRS et le SARS-CoV-2 dans des modèles animaux.
Le mécanisme unique de NV-387 imite une caractéristique côté hôte utilisée par 90-95 % des virus pathogènes humains, rendant difficile le développement de résistance par les virus. La taille totale du marché pour les indications de NV-387 est estimée à dépasser $10 milliards. L'entreprise a également développé une plateforme permettant aux médicaments non oraux d'être délivrés comme des médicaments oraux actifs.
NanoViricides (NYSE American:NNVC) hat seine bevorstehende Präsentation beim Biotech Showcase™ 2025 in San Francisco am Dienstag, den 14. Januar 2025, um 14:30 Uhr PT angekündigt. Die Präsentation findet im Hilton San Francisco - Union Square statt.
Das Unternehmen wird sein Phase-II-bereites Medikament NV-387 vorstellen, das eine breit gefächerte antivirale Aktivität gezeigt hat. NV-387 hat sich als wirksamer erwiesen im Vergleich zu bestehenden Behandlungen wie Tamiflu®, Rapivab® und Xofluza® zur Behandlung von Influenza A. Das Medikament hat auch vielversprechende Ergebnisse gegen Infektionen mit MPox, Pocken, RSV und SARS-CoV-2 in Tiermodellen gezeigt.
Der einzigartige Mechanismus von NV-387 ahmt ein Merkmal der Wirtsseite nach, das von 90-95 % der humanpathogenen Viren verwendet wird, was es den Viren erschwert, Resistenzen zu entwickeln. Die Gesamtgröße des Marktes für die NV-387-Indikationen wird auf über $10 Milliarden geschätzt. Das Unternehmen hat auch eine Plattform entwickelt, die es ermöglicht, nicht-orale Medikamente als aktive orale Medikamente zu verabreichen.
- None.
- None.
SHELTON, CT / ACCESSWIRE / January 13, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced today that it is presenting at Biotech Showcase™ 2025 in San Fransisco, being held in parallel to the JP Morgan Life Sciences Conference.
Event Information:
Event | NanoViricides Presentation at the Biotech Showcase, San Fransisco |
Day & Date | Tuesday, January 14, 2025 |
Time, Track & Room | 2:30pm PT, Yosemite A (Ballroom Level) |
Location | Hilton San Fransisco - Union Square |
Anil R. Diwan, PhD, President and Executive Chairman of the Company will provide an update on the Company, its Drug Pipeline and Technologies available for licensing.
The Phase II-ready drug NV-387 has demonstrated extremely broad antiviral spectrum of activity in animal models, which could prove to be as revolutionary for viral infections as penicillin was for bacterial infections. This broad spectrum is because NV-387 is designed to mimic a host-side feature that is used by over 90
In light of the concerns regarding H5N1 Bird Flu and its potential spread, NV-387 is one of the most promising candidates that can respond to an Influenza pandemic. The Influenza virus would be unable to escape the NV-387 drug treatment because this drug mimics the feature on the host-side that all Influenza viruses continue to use for causing an infection, even as they evolve rapidly in the field.
NV-387 has demonstrated activity substantially superior to each of oseltamivir (Tamiflu®), peramivir (Rapivab®), and baloxavir (Xofluza®) in lethal animal models of Influenza A lung viral infection. These approved drugs as well as vaccines and antibodies are readily escaped by the virus as it evolves in the field.
NV-387 has also shown strong activity in lethal animal model studies for MPox and Smallpox treatment developments. There is no drug for the treatment of MPox infection at present. MPox Clade 1 and 1b infections have caused a continuing pandemic in the Africa that led to WHO declaring a Public Health Emergency of International Concern (PHEIC) in August 2024.
NV-387 has demonstrated cure of lethal RSV infection in animal model studies. There is no drug for the treatment of RSV infection at present, except for the last resort toxic drug ribavirin.
NV-387 has demonstrated strong activity against coronavirus lethal animal models for SARS-CoV-2 infection (COVID-19).
In addition, the Company has developed a platform that enables important non-oral drugs to be delivered as active oral drugs, which we believe is a sought after technology by Pharma companies.
The overall market size of NV-387 indications is estimated to be well in excess of
This year, registered attendees can view NanoViricides' presentation live, and also access a recorded version after the event. With 24x7 on-demand access, attendees can view recorded presentations at their convenience when scheduling does not allow viewing during the main event week.
Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities. The conference takes place each year in San Francisco during the course of one of the industry's largest gatherings and busiest weeks.
ABOUT BIOTECH SHOWCASE
Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather at Biotech Showcase during this bellwether week which sets the tone for the coming year. Now in its 16th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.
NanoViricides, Inc. (the "Company") (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company's novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.
The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company's business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.
Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.
NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.
The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.
This press release contains forward-looking statements that reflect the Company's current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company's expectations include, but are not limited to, those factors that are disclosed under the heading "Risk Factors" and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.
The phrases "safety", "effectiveness" and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.
FDA refers to US Food and Drug Administration. IND application refers to "Investigational New Drug" application. cGMP refers to current Good Manufacturing Practices. CMC refers to "Chemistry, Manufacture, and Controls". CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency's (EMA) committee responsible for human medicines. API stands for "Active Pharmaceutical Ingredient". WHO is the World Health Organization. R&D refers to Research and Development.
Contact:
NanoViricides, Inc.
info@nanoviricides.com
Public Relations Contact:
ir@nanoviricides.com
SOURCE: NanoViricides
View the original press release on accesswire.com
FAQ
What are the key features of NanoViricides' NV-387 drug presented at Biotech Showcase 2025?
How does NNVC's NV-387 compare to existing influenza treatments?
What is the estimated market size for NV-387's indications according to NNVC?
When and where will NanoViricides (NNVC) present at Biotech Showcase 2025?
What viral infections has NNVC's NV-387 shown effectiveness against in animal studies?
